ALK-positive anaplastic large cell lymphoma
GPTKB entity
Statements (53)
| Predicate | Object |
|---|---|
| gptkbp:instance_of |
gptkb:healthcare_organization
|
| gptkbp:associated_with |
anaplastic lymphoma kinase (ALK) gene
|
| gptkbp:clinical_trial |
ongoing research
phase II trials phase III trials |
| gptkbp:first_described_by |
1990s
|
| gptkbp:genetic_diversity |
T P53 mutations
ALK fusion protein NPM-ALK |
| https://www.w3.org/2000/01/rdf-schema#label |
ALK-positive anaplastic large cell lymphoma
|
| gptkbp:is_characterized_by |
rearrangement of the ALK gene
|
| gptkbp:is_often_used_in |
younger adults
|
| gptkbp:related_to |
gptkb:healthcare_organization
|
| gptkbp:research_focus |
improving patient outcomes
understanding resistance mechanisms biomarkers for diagnosis new therapeutic targets |
| gptkbp:risk_factor |
age
gender genetic predisposition |
| gptkbp:social_responsibility |
more common in males
biopsy cell signaling pathways immune evasion mechanisms generally favorable rare disease immunohistochemistry cytokine production microenvironment interactions fluorescence in situ hybridization (FISH) incidence rate low associated with EBV geographic variation in incidence involves genetic alterations |
| gptkbp:symptoms |
fatigue
weight loss fever night sweats lymphadenopathy |
| gptkbp:treatment |
gptkb:brentuximab_vedotin
gptkb:vaccine gptkb:alectinib gptkb:ceritinib gptkb:crizotinib chemotherapy targeted therapy long-term survival possible variable response to therapy monitoring required post-treatment potential for relapse |
| gptkbp:type_of |
gptkb:non-Hodgkin_lymphoma
|
| gptkbp:bfsParent |
gptkb:anaplastic_lymphoma
|
| gptkbp:bfsLayer |
7
|